Target Name: KCTD19
NCBI ID: G146212
Other Name(s): potassium channel tetramerisation domain containing 19 | Potassium channel tetramerization domain containing 19 | KCD19_HUMAN | BTB/POZ domain-containing protein KCTD19 | potassium channel tetramerization domain containing 19 | testicular tissue protein Li 101

KCTD19: A Potassium Channel Tetramerisation Domain Containing 19 as A Drug Target Or Biomarker

Unlocking the Potential of KCTD19: A Potassium Channel Tetramerisation Domain Containing 19 as a Drug Target or Biomarker

Introduction

KCTD19, a member of the superfamily of voltage-gated potassium channels, has been identified as a potential drug target or biomarker. Its unique structure, consisting of four transmembrane segments and a variable charge state, makes KCTD19 very potent in nerve and muscle cells. high expression levels. In addition, the function and expression pattern of KCTD19 play a key role in various physiological processes, such as cell excitability, autonomy, conduction velocity, etc. Therefore, in-depth study of the function and mechanism of KCTD19 is of great significance for understanding and developing new drugs.

1. Basic structure and functions of KCTD19

KCTD19 is a transmembrane protein whose main feature is four highly conserved helical structures. KCTD19 consists of 19 amino acids and its molecular weight is approximately 30 kDa. KCTD19 forms four transmembrane 伪-helices on the cell membrane, which are arranged in a right-handed helix at both ends of the membrane. Among the four 伪-helices of KCTD19, the first and fourth helices are located on the inside of the cell membrane, while the second and third helices are located on the outside of the cell membrane.

The main function of KCTD19 is to regulate the resting potential and action potential of the cell membrane. In the resting state, KCTD19 is at a relatively stable potential state, maintaining the permeability and stability of the cell membrane. When cells are stimulated, KCTD19 generates action potentials, leading to rapid, reversible changes in cell membrane potential. This change plays a key role in physiological processes such as the excitability and conduction speed of nerve and muscle cells.

2. The mechanism of action of KCTD19

The mechanism of action of KCTD19 mainly involves the following aspects:

1. Regulate the resting potential of cell membrane

The resting potential state of KCTD19 is determined by the charge distribution of its four 伪-helices. In the resting state, the four 伪-helices of KCTD19 carry a common charge. This charge state causes the two sides of KCTD19 to attract each other to form a stable structure. When cells are stimulated, KCTD19 generates action potentials, leading to rapid, reversible changes in cell membrane potential.

2. Regulate the action potential of cell membranes

The action potential state of KCTD19 is determined by the charge changes of its four 伪-helices. During the action potential, the first and third 伪-helices of KCTD19 carry a common positive charge, while the second and fourth 伪-helices carry a common negative charge. This charge change leads to an imbalance of charges on both sides of KCTD19, thereby forming an action potential.

3. Participate in cell signaling

KCTD19 plays an important role in cell signaling. Studies have shown that the 伪-helical structure of KCTD19 is involved in the open state of voltage-dependent ion channels (such as potassium ion channels) on the cell membrane. This open state allows potassium ion plasma to move rapidly across the cell membrane, triggering a series of signaling processes.

3. Pharmacological significance of KCTD19

As a protein with unique structure and function, KCTD19 is considered a potential drug target. By studying the function of KCTD19, new drug targets can be discovered and a deeper understanding of the role of potassium channels in physiological and pathological processes can be obtained.

1. Anti-neurodegenerative disease drugs

Neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, are closely related to the abnormal open state of potassium ion channels. Studies have found that KCTD19 is involved in the occurrence and development of neurodegenerative diseases, providing a new target for the development of anti-neurodegenerative disease drugs.

2. Antiarrhythmic drugs

Arrhythmia is a common cardiovascular disease related to the abnormal open state of potassium ion channels. KCTD19 has a potential role in regulating arrhythmias. Therefore, the research on antiarrhythmic drugs has also become an important development direction of KCTD19.

3. Muscle contraction regulating drugs

Muscle contraction is an important process of skeletal muscle contraction and plays an important role in maintaining normal physiological functions of the human body. KCTD19 plays a key role in regulating muscle contraction. Therefore, the research on muscle contraction regulating drugs has also become a

Protein Name: Potassium Channel Tetramerization Domain Containing 19

More Common Targets

KCTD2 | KCTD20 | KCTD21 | KCTD21-AS1 | KCTD3 | KCTD4 | KCTD5 | KCTD5P1 | KCTD6 | KCTD7 | KCTD8 | KCTD9 | KDELR1 | KDELR2 | KDELR3 | KDF1 | KDM1A | KDM1B | KDM2A | KDM2B | KDM3A | KDM3B | KDM4A | KDM4B | KDM4C | KDM4D | KDM4E | KDM5A | KDM5A-GATAD1-EMSY chromatin complex | KDM5B | KDM5C | KDM5D | KDM6A | KDM6B | KDM7A | KDM7A-DT | KDM8 | KDR | KDSR | KEAP1 | Kelch-like protein | KERA | Keratin | KHDC1 | KHDC1L | KHDC1P1 | KHDC3L | KHDC4 | KHDRBS1 | KHDRBS2 | KHDRBS3 | KHK | KHNYN | KHSRP | KHSRPP1 | KIAA0040 | KIAA0087 | KIAA0232 | KIAA0319 | KIAA0319L | KIAA0408 | KIAA0513 | KIAA0586 | KIAA0753 | KIAA0754 | KIAA0825 | KIAA0930 | KIAA1107 | KIAA1143 | KIAA1191 | KIAA1210 | KIAA1217 | KIAA1328 | KIAA1522 | KIAA1549 | KIAA1549L | KIAA1586 | KIAA1614 | KIAA1656 | KIAA1671 | KIAA1671-AS1 | KIAA1755 | KIAA1958 | KIAA2012 | KIAA2013 | KIAA2026 | KICS2 | KIDINS220 | KIF11 | KIF12 | KIF13A | KIF13B | KIF14 | KIF15 | KIF16B | KIF17 | KIF18A | KIF18B | KIF19 | KIF1A